about
Clinical implications of the Women's Ischemia Syndrome Evaluation: inter-relationships between symptoms, psychosocial factors and cardiovascular outcomesCardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome EvaluationTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationPopulation approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association.Tree-based identification of subgroups for time-varying covariate survival data.Practical interpretation of 6-minute walk data using healthy adult reference equations.Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial).Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure.Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data.Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular eventsThe relationship of menopausal status and rapid menopausal transition with carotid intima-media thickness progression in women: a report from the Los Angeles Atherosclerosis Study.Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria?Perspectives on dyslipidemia and coronary heart disease in women.Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study.Women and coronary heart disease risk factors.Self-rated versus objective health indicators as predictors of major cardiovascular events: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.Cardiac rehabilitation outcomes: impact of comorbidities and ageWomen in cardiac rehabilitation.Relationships between cardiovascular disease risk factors and depressive symptoms as predictors of cardiovascular disease events in womenPrognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) studyIsolated diastolic hypotension and incident heart failure in older adultsInsights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvasculInsights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.Cardiac rehabilitation as secondary prevention center.Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsPerspectives on dyslipidemia and coronary heart disease in women: an update.Health-related quality of life following coronary artery bypass graft surgery in post-menopausal womenLeft Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failureAnginal symptoms, coronary artery disease, and adverse outcomes in Black and White women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) studyTrends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010Association of race and sex with risk of incident acute coronary heart disease eventsThe triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE).The joint impact of smoking and exercise capacity on clinical outcomes among women with suspected myocardial ischemia: the WISE study.Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialBiomarkers of atherosclerosis: clinical applicationsPredictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program.
P50
Q26861338-03E6685F-4C45-46B1-9DF5-D0EE80B6CFB4Q28193306-9F757538-DDD7-434D-92D8-F6D1E306458EQ28196401-53A3420D-1B31-4F96-AB2F-2FFD82FC266DQ28235865-D7FCF7A1-1970-4B2F-A825-6E4844FCD253Q28393776-75ED9972-FB20-4585-90A5-ABCC3275658EQ30573568-2E9E82B5-D6EE-4C6C-A351-14CC3E836FDAQ33245322-AF442E79-1038-44F6-8E4D-647AD2D74194Q33546757-94CCB1F9-C26A-424C-8202-29560C4352B9Q33738575-468FEECE-E41E-4BF1-A177-442D62B7DC7CQ33879957-61E61A2B-0B9F-493F-9003-F9BE219584F4Q33885656-6B883DAE-73AE-474E-A586-A37B72499F1FQ34012463-B710FC85-ED0C-4C3B-BA7C-EF007525E8BEQ34080023-E9DF4C78-9368-4805-9E63-3BCFBBDAE5A1Q34113174-01EDD439-A96A-4102-B18D-A891851BFF44Q34141982-CB47C38D-D202-42E0-9D7C-2BC77E33E488Q34562153-D8ACB2C1-16B6-46FA-83F6-99A0A5A97FE0Q34567765-1A101602-56AF-4CAA-9747-BC5E825B7523Q35023801-234AD40E-B7A6-4000-A3AC-EE13F8EA6F17Q35040751-87E20C44-2D7A-4783-83C5-B6126F604EDAQ35560722-B05321FE-287D-428B-BFB6-A46352925FE1Q35593727-BADA6093-3CEA-4A55-9388-52FEBE638F83Q35721814-C95C4D82-9F5A-4357-84D7-3664E0E54783Q35754796-9996A71D-CCE6-4FAB-B909-E654FB1F5D8AQ36077111-BDA8C8E5-14B9-4F9D-BECD-CED44B37E0F3Q36386697-0B21143D-456E-4842-9A0C-2BDD65AAB273Q36386704-A02F7985-62CF-4851-8C84-C0EB42FB2CE4Q36490006-D14A4640-E2B7-4989-BE4A-24E33BFE5FD5Q36536790-057FC6A4-2AFF-41CF-B1D3-4A11940851B7Q36629224-DA4A3870-E43E-4682-BE5A-29D6ED3C42BBQ36841069-72F9A3B1-BFB1-4F30-AEF9-259C7DE90DD7Q37148978-535A8689-C41A-43F6-BEB8-C34F62E915A6Q37155662-BBE4ACAD-F982-4710-941C-05E46FC0E96AQ37158788-2D18D580-B464-419B-BA2E-F98740B64023Q37160435-9E47B241-1516-43B3-BA8C-E998B35088A1Q37169579-DE4BC777-36A8-4D8E-BD4B-F151E605F1CCQ37180795-3DE17E2B-C754-42EC-BCFD-4A4864B65ACDQ37199289-3B63BCEC-7415-4345-9958-73282554C5ECQ37280331-E0BBD00F-2A70-49DC-A065-E9628553E50BQ37307999-2EB43AC9-F033-4F28-BFB1-BB705F356C8CQ37383851-A5CB64E5-B030-408A-8514-6A63A963822A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vera Bittner
@ast
Vera Bittner
@en
Vera Bittner
@es
Vera Bittner
@nl
Vera Bittner
@sl
type
label
Vera Bittner
@ast
Vera Bittner
@en
Vera Bittner
@es
Vera Bittner
@nl
Vera Bittner
@sl
prefLabel
Vera Bittner
@ast
Vera Bittner
@en
Vera Bittner
@es
Vera Bittner
@nl
Vera Bittner
@sl
P106
P21
P31
P496
0000-0001-9456-850X